Infusion of an oxytocin antagonist into the medial preoptic area prior to progesterone inhibits sexual receptivity and increases rejection in female rats.
Central administration of an antagonist to the neuropeptide oxytocin (OT) has been shown to block the progesterone-induced facilitation of female sexual receptivity. In this study we examined the effects of infusing an OT antagonist (OTA) into various brain sites before rats were injected with 250 micrograms progesterone (P). Ovariectomized animals were injected daily for three consecutive days with 1 microgram estradiol benzoate and then on the fourth day were infused into the medial preoptic area (MPOA), medial basal hypothalamus (MBH) or ventral tegmental area with either 250 ng/microliter/side OTA or artificial cerebrospinal fluid vehicle. Animals were tested in an arena made of two white polyethylene cages connected by a tunnel that allowed passage of the female but not of the larger male. Several receptive and non-receptive behaviors were recorded for a 15-min period beginning 4 hr after P injection. Animals infused with OTA into the MPOA before P showed an increase in the frequency and total duration of fighting with males and the frequency of audible vocalizations made by females. OTA infusions also increased the frequency of mounts that did not result in a lordosis posture. OTA infusions into the MPOA also reduced the frequency and total duration of lordosis postures in response to mounts. OTA infusions into the MBH and VTA had no effect on measures of sexual behaviors. Blocking OT transmission in the MPOA resulted in increased rejection behaviors and decreased receptivity in females when infused before systemic P injection.
Caldwell
J D
JD
Department of Psychiatry, School of Medicine, University of North Carolina at Chapel Hill 27599.
Johns
J M
JM
Faggin
B M
BM
Senger
M A
MA
Pedersen
C A
CA
D000818:Animals; D001931:Brain Mapping; D004924:Escape Reaction / Q000187:drug effects / Q000502:physiology; D005260:Female; D008297:Male; D009433:Neural Inhibition / Q000187:drug effects* / Q000502:physiology; D010121:Oxytocin / Q000037:antagonists & inhibitors* / Q000502:physiology; D011292:Premedication; D011301:Preoptic Area / Q000187:drug effects* / Q000502:physiology; D011374:Progesterone / Q000494:pharmacology* / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012726:Sexual Behavior, Animal / Q000187:drug effects* / Q000502:physiology; D014668:Vasotocin / Q000031:analogs & derivatives* / Q000494:pharmacology
C076093:vasotocin, (beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)-O-methyl-Tyr(2)-Thr(4)-Orn(8)-Tyr(9)-NH2; D011374:Progesterone; D010121:Oxytocin; D014668:Vasotocin